MicroRNA 4317 (miR-4317)

MicroRNA 4317 (miR-4317) is a small, non-coding RNA molecule transcribed from the MIR4317 gene and processed into a mature miRNA by Drosha and Dicer enzymes[3][5]. As part of the RNA-induced silencing complex (RISC), it binds to partially complementary sequences in target mRNAs, leading to downregulation via degradation or translational repression. miR-4317 has been identified as a suppressor of cancer cell proliferation, migration, and invasion in multiple tumor types. In NSCLC, it inhibits tumor growth by targeting FGF9 and CCND2, and systemic administration of agomiR-4317 reduces metastasis in mouse models[1]. Studies also show roles in breast cancer, gastric cancer (via ZNF322), and hepatocellular carcinoma (via ZNF436/PI3K-AKT)[2][3][4][6]. Reduced miR-4317 expression is associated with advanced tumors and poorer prognosis, making it a candidate biomarker and potential therapeutic target for cancer[1][6].

Other names

miR-4317MIR4317hsa-mir-4317microRNA-4317

RNA-based therapeutics (agomirs) mimic or restore miR-4317 function to suppress oncogenic targets. miR-4317 inhibits cell growth and metastasis by direct downregulation of target genes, such as fibroblast growth factor 9 (FGF9), cyclin D2 (CCND2), ZNF322, and ZNF436. Pathways impacted include PI3K/AKT signaling and cell cycle regulation.